As previously reported, Wedbush analyst David Nierengarten downgraded Avrobio to Neutral from Outperform with an unchanged price target of $2 after the company announced that it is stopping development of its gene therapy programs and will pursue strategic alternatives. The firm’s price target reflects existing cash levels minus separation costs that are likely to occur in Q3 as the company expects to cut about 50% of its workforce by the end of July and said remaining employees will support efforts to pursue alternatives.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AVRO: